Tissues is a group of human cells that play a vital role in performing various biological functions that are important for other healthy functions in a human body.
As these layers of cells carry extremely important elements of information about the health prospects of the body, tissue samples are commonly taken to analyse and diagnose various health conditions, as they capture the biological specification of any disease.
Tissue diagnostics is emerging as an important field of diagnostics research as tissue samples can explain various aspects of different biological conditions. Especially in the field of cancer diagnostics and analysis, tissue diagnostics have played a key role as it has helped scientists and researchers identify the presence of cancer upon examining the tissue samples.
Tissue diagnostics is also gaining immense popularity in the other diagnostics areas where origin and treatment of different other chronic diseases are being studied by leading pharmaceutical companies.
Histopathology is among the most commonly implemented methods of tissue diagnostics, and it involves the analysis with tissue samples through various processes such as fine needle aspiration cytology, small biopsies, and open biopsy or surgery.
Other important types of tissue diagnostics are in situ hybridization, Immunohistochemistry (IHC), and Hematoxylin and Eosin (H&E). Based on the tissue samples under observation, the motive of the diagnostics, and other specific conditions, the method of tissue diagnostics is decided.
Advent of Digital Pathologies to Transform the Modern Tissue Diagnostics Landscape
Diagnostic laboratories or pathologies have worked on the traditional model for years, where microscopes have been the go-t0 instrument for pathologists worldwide. However, the rise of digitalization across the entire healthcare industry is triggering the adoption of modern technologies that can digitally transform conventional models of pathologies.
A majority of healthcare businesses are entering the digital era with the establishment of new digital pathology systems that are equipped with the network of high-definition tissue diagnostics instruments.
The modern diagnostics laboratories are shifting from the traditional devices for studying and examining magnified tissue samples to diagnose different health conditions to more modern and high-tech instruments in the innovative diagnostics environment called digital pathologies.
The adoption of whole-slide imaging (WSI) among various other tech-driven diagnostic tools is on the rise, and this has defined an emerging trend in the digital pathology set up.
Leading players in the tissue diagnostics market are realising this shift in the operational models of pathologies and diagnostic laboratories to modify their offerings and features of their services.
In the coming years, the rise of digital pathologies will become more prevalent, triggering all the stakeholders in the tissue diagnostics market to acquire advanced technologies to offer the new-age tissue diagnostics products in the coming years.
Ongoing Research in the Diagnostics of Cancer will Primarily Boost Demand
Growing prevalence of cancer across the world has triggered a significant rise in the research & development activities in the tissue diagnostics field. With over 18 million new cases and more than 9.6 million deaths due to cancer, the global cancer burden increased alarmingly in 2018, according to the World Health Organization (WHO).
The global tissue diagnostics market is expected to witness rising collaborations between research institutions and market players in the area of cancer research.
For instance, in June 2020, the University of Sheffield, United Kingdom, inked its collaboration with Zilico Ltd - a UK-based company which specialises in the design and manufacture of real-time medical diagnostics to address specific clinical needs - to invent a non-invasive, pain-free, and instantaneous method to diagnose oral cancer with the implementation of its electrical impedance spectroscopy (EIS) technology.
In the same month, Epredia - a global leader in precision cancer diagnostics and tissue diagnostics, announced that it is entering a strategic distribution agreement with Lunaphore Technologies SA - a Swiss life-sciences company that specialised in the development of innovative next-generation equipment for cancer research.
Lunaphore is a leading supplier and manufacturer of tissue staining instruments, and it will integrate Fast Fluidic Exchange microfluidic technology with its tissue diagnostics instruments for uniform and rapid delivery of reagents to tissue samples through rapid immunohistochemistry (IHC) and immunofluorescence (IF).
Tissue Diagnostics Market: Region-wise Analysis
Based on the geographical factors, the tissue diagnostics market is broadly divided into seven regions - North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa.
An alarming rise in the prevalence of life-threatening diseases including cancer, in the United States is triggering the cancer research and diagnostics activities in the North American region. This is expected to aid the growth of the tissues diagnostics market in the region, grabbing a significantly high revenue share of the global market.
Furthermore, governing bodies in the North American region are bolstering their investments in the cancer research facilities.
For instance, the Centers for Disease Control and Prevention (CDC) has established its flagship program - The Cancer Prevention and Control Research Network - which mainly focuses on encouraging cancer research and prevention projects in the region.
Leading players are investing heavily in tissue diagnostics tools in order to capitalize on the rise in growth of the personalised medicines industry. On the other hand, developing countries in the Asia Pacific region, especially China and India, are expected to witness a significant rise in development of tissue diagnostics assays.
Tissue Diagnostics Market: Competitive Landscape
- Agilent Technologies
- Danaher Corporation
- F. Hoffmann-La Roche AG
- bioMérieux SA
- Abbott Laboratories
- Sigma-Aldrich Co. LLC
- Ventana Medical Systems
- GE Healthcare
- Cell Signaling Technology.
Leading players in the tissue diagnostics market are increasing their attention to the rise in the use of tissue diagnostics devices in digital pathologies. This is expected to trigger strategic collaborations among technology providers and digital pathology platforms in the global tissue diagnostics market in the coming years.
For instance, in July 2020, Koninklijke Philips N.V. - a Dutch multinational conglomerate corporation and one of the world’s largest electronics companies with the focus on the area of health technology - announced that it has collaborated with Proscia Inc. - a Philadelphia-based provider of digital pathology platform - to establish an open ecosystem for diagnostic laboratories to boost and scale their operations on the platform of digital pathologies.
As a part of this collaboration, Proscia will begin to utilize Philips’ iSyntax image format, which will be integrated with the Philips Pathology SDK software toolset, along with its suite of artificial intelligence modules across its Concentriq digital pathology platform.
In June 2020, F. Hoffmann-La Roche AG - a Swiss multinational healthcare company that operates worldwide under pharmaceuticals and diagnostics divisions - announced the CE-IVD launch of its state-of-the-art and fully automated digital pathology platform - uPath PD-L1 (SP263) to increase the focus on the research around non-small cell lung cancer (NSCLC). The company declared that the motive behind its move was to improve the certainty and consistency in diagnostic laboratories through image analysis tools integrated with artificial intelligence technology.
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, U.K., France, Italy, Spain, Poland, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, Thailand, Malaysia, Vietnam, Indonesia)
- Oceania (Australia, New Zealand)
- Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Tissue Diagnostics Market: Segment Analysis
The tissue diagnostics market can be segmented on the basis of the following:
- Lung Cancer
- Breast Cancer
- Non-contact Handheld IR Thermometer
- NMR Tube
- Reagent Kits
- In Situ Hybridization
- Hematoxylin and Eosin (H&E)
- Immunohistochemistry (IHC)
By End User
- Diagnostic Laboratories
- Contract Research Organizations
- Research Organizations
- Biotechnology Companies
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.